AR095132A1 - Formulación en dispersión sólida de un compuesto antiviral - Google Patents

Formulación en dispersión sólida de un compuesto antiviral

Info

Publication number
AR095132A1
AR095132A1 ARP140100354A ARP140100354A AR095132A1 AR 095132 A1 AR095132 A1 AR 095132A1 AR P140100354 A ARP140100354 A AR P140100354A AR P140100354 A ARP140100354 A AR P140100354A AR 095132 A1 AR095132 A1 AR 095132A1
Authority
AR
Argentina
Prior art keywords
compound
formulation
solid dispersion
antiviral compound
disclosed
Prior art date
Application number
ARP140100354A
Other languages
English (en)
Inventor
Oliyai Reza
Gorman Eric
Mogalian Erik
Stefanidis Dimitrios
Zia Vahid
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of AR095132A1 publication Critical patent/AR095132A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se divulgan dispersiones sólidas que comprenden un compuesto que tiene la fórmula (1) caracterizadas porque el compuesto es dispersado dentro de una matriz polimérica formada por un polímero aceptable desde el punto de vista farmacéutico, y caracterizadas además porque el compuesto es sustancialmente amorfo. También, se divulgan las composiciones farmacéuticas que comprenden el compuesto así como los métodos de uso para el compuesto.
ARP140100354A 2013-08-27 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral AR095132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361870703P 2013-08-27 2013-08-27

Publications (1)

Publication Number Publication Date
AR095132A1 true AR095132A1 (es) 2015-09-30

Family

ID=50097890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100354A AR095132A1 (es) 2013-08-27 2014-01-31 Formulación en dispersión sólida de un compuesto antiviral

Country Status (5)

Country Link
US (1) US20150064252A1 (es)
AR (1) AR095132A1 (es)
TW (1) TW201511780A (es)
UY (1) UY35301A (es)
WO (1) WO2015030854A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI607011B (zh) 2010-11-17 2017-12-01 基利法瑪席特有限責任公司 抗病毒化合物
WO2013075029A1 (en) 2011-11-16 2013-05-23 Gilead Sciences, Inc. Condensed imidazolylimidazoles as antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CN107343877A (zh) * 2016-05-06 2017-11-14 常州爱诺新睿医药技术有限公司 一种无定型维帕他维的固体分散体及其制备方法
BR102017011025A2 (pt) * 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
BR0307333A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
CN100528875C (zh) 2005-02-18 2009-08-19 美德(江西)生物科技有限公司 无结晶型态的印地普隆及其制备方法
BRPI0719395C1 (pt) * 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd tablete revestido de filme
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
TWI607011B (zh) * 2010-11-17 2017-12-01 基利法瑪席特有限責任公司 抗病毒化合物
WO2013075029A1 (en) 2011-11-16 2013-05-23 Gilead Sciences, Inc. Condensed imidazolylimidazoles as antiviral compounds
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
WO2015030854A1 (en) 2015-03-05
UY35301A (es) 2015-03-27
TW201511780A (zh) 2015-04-01
US20150064252A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
UY35298A (es) Formulación en dispersión sólida de un compuesto antiviral
AR095132A1 (es) Formulación en dispersión sólida de un compuesto antiviral
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
UY37098A (es) Moduladores de ror-gamma
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
UY35300A (es) Formulación de combinación de dos compuestos antivirales
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2018000786A1 (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
NI201800058A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer.
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
CL2019001993A1 (es) Inhibidores selectivos de jak1.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
CR20160438A (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación
PH12016500793A1 (en) Turmeric extract containing soft pastilles

Legal Events

Date Code Title Description
FB Suspension of granting procedure